Rubric Capital Management LP Increases Stake in ARS Pharmaceuticals, Inc. to 8.06%

On May 15, 2026, Rubric Capital Management LP and David Rosen filed a Schedule 13G/A with the SEC, reporting an increased stake in ARS Pharmaceuticals, Inc. (SPRY). The reporting persons now collectively beneficially own 8,000,000 shares of common stock, representing an 8.06% ownership stake in the company based on 99,297,307 shares outstanding as of March 4, 2026. This filing serves as an amendment to a previous statement, marking a significant increase from the previously reported position of zero shares. Rubric Capital Management LP acts as the investment adviser to various funds, including the Rubric Capital Master Fund LP, which holds more than 5% of the shares. David Rosen, the Managing Member of Rubric Capital Management GP LLC, shares voting and dispositive power over these securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The principal business office for the reporting persons is located in New York, NY.